Industry News
Pharmaceutical Industry News
The 100% rate floated in Donald…
The 100% rate floated in Donald Trump’s new communique on pharmaceutical tariffs may appear steep, but the reality of the situation is likely less severe than it seems, multiple analysts wrote Friday following the president’s
Celltrion is buying an Eli Lilly…
Celltrion is buying an Eli Lilly plant in the U.S. for $330 million. The FDA has declined to approve Lundbeck and Otsuka's Rexulti in PTSD. Hengrui Pharma has out-licensed certain rights to its HER2 ADC
Serial entrepreneur Robert…
Serial entrepreneur Robert Wessman, who has had a golden touch creating, acquiring and spinning off companies that primarily sell generic drugs, has brought together two of his fastest-growing enterprises as Lotus Pharmaceuticals has acquired a 100%
Trump Will Slap Tariffs on Imported Drugs, Trucks and Household Furnishings
The president said his tariffs would range from 25 to 100 percent and go into effect next week.
Trump May Try to Force Drugmakers to Match European Prices
A federal website notice, deleted and then reposted by the administration, provides a hint that more aggressive pricing policies may be coming.
Eli Lilly has won the second FDA…
Eli Lilly has won the second FDA approval for an oral selective estrogen receptor degrader (SERD), albeit in a confined breast cancer indication like Menarini's drug before it.
At Fierce Pharma Week in…
At Fierce Pharma Week in Philadelphia, Veeva’s Anthony Billinger, Senior Director of Compass Strategy, emphasized the challenges drugmakers face in bringing new products to market, pointing to a persistent gap between forecasts and results. Studies
The FDA on Thursday signed off on…
The FDA on Thursday signed off on Crinetics’ paltusotine—now christened Palsonify—as a first-line treatment for certain adults with acromegaly. Unlike other somatostatin drugs that make up the bulk of current acromegaly care options, Palsonify is
Patients don’t just want to be…
Patients don’t just want to be reached. They want support that reduces barriers and makes progress easier. Here’s how pharma can deliver value that sustains engagement and adherence.
Hansa Biopharma has reported…
Hansa Biopharma has reported positive top-line results from a U.S. phase 3 trial of its antibody-cleaving enzyme imlifidase, which boasts conditional nods in the EU and several other countries to ease the kidney transplant process
Times Reporters Answer Your Vaccine Questions
We received hundreds of queries about efficacy, safety, cost and access.
On the heels of the launch of an…
On the heels of the launch of an online direct-to-patient program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP project.
With an appeal to the Supreme…
With an appeal to the Supreme Court, AstraZeneca is throwing one last Hail Mary following a string of Big Pharma defeats challenging the legality of the Inflation Reduction Act (IRA) Medicare price negotiation program.
Belén Garijo, who steered Merck…
Belén Garijo, who steered Merck KGaA through the COVID-19 pandemic, will step down as CEO of the German healthcare and electronics conglomerate.
After being pushed by attorneys…
After being pushed by attorneys general from 22 states, U.S. healthcare leaders are taking another look at the circumstances under which mifepristone can be prescribed.
Guardant Health is joining in on…
Guardant Health is joining in on the American Lung Association’s push to raise awareness about lung cancer screening and biomarker testing.
Moderna has opened the doors to…
Moderna has opened the doors to its long-anticipated Harwell vaccine production facility in the U.K. The facility debut comes as Moderna's competitors take shots at British life sciences policies and retreat from previously planned projects
Un decano de Harvard cobró 150.000 dólares como perito en las demandas contra Tylenol
El gobierno de Trump ha citado la pericia de Andrea Baccarelli para advertir contra el uso del paracetamol —el principio activo del Tylenol— en el embarazo, basándose en una relación no demostrada con el autismo.
Soleno Therapeutics is breathing…
Soleno Therapeutics is breathing easier with a report from Acadia Pharmaceuticals that its candidate to treat hyperphagia in patients with Prader-Willi Syndrome has come up short in a phase 3 trial and has been scrapped
The vast majority of drugmakers…
The vast majority of drugmakers are either considering or have already established direct-to-patient programs, cutting out middlemen to offer services like virtual care consultations, payment support, at-home diagnostics and digital pharmacies.